We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Scynexis Inc | NASDAQ:SCYX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.03 | 1.78% | 1.72 | 1.71 | 1.79 | 1.74 | 1.61 | 1.66 | 63,820 | 01:00:00 |
|
|
|
ý
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
Delaware
|
|
56-2181648
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
101 Hudson Street
Suite 3610
Jersey City, New Jersey
|
|
07302-6548
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
Large accelerated filer
|
¨
|
|
|
Accelerated filer
|
|
ý
|
|
|
|
|
|||
Non-accelerated filer
|
¨
|
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
¨
|
|
|
|
|
|
|
|
Emerging growth company
|
ý
|
|
|
|
|
|
|
|
|
|
Page
|
Item 1.
|
||
|
||
|
||
|
||
|
||
Item 2.
|
||
Item 3.
|
||
Item 4.
|
||
|
|
|
|
|
|
Item 1A.
|
||
Item 6.
|
||
|
|
|
Item 1.
|
Financial Statements
|
|
March 31, 2017
|
|
December 31, 2016
|
||||
Assets
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
19,908
|
|
|
$
|
35,656
|
|
Short-term investments
|
34,991
|
|
|
22,930
|
|
||
Prepaid expenses and other current assets
|
691
|
|
|
741
|
|
||
Total current assets
|
55,590
|
|
|
59,327
|
|
||
Other assets
|
730
|
|
|
120
|
|
||
Deferred offering costs
|
335
|
|
|
345
|
|
||
Total assets
|
$
|
56,655
|
|
|
$
|
59,792
|
|
Liabilities and stockholders’ equity
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable
|
$
|
2,044
|
|
|
$
|
2,192
|
|
Accrued expenses
|
1,057
|
|
|
1,268
|
|
||
Deferred revenue, current portion
|
257
|
|
|
257
|
|
||
Total current liabilities
|
3,358
|
|
|
3,717
|
|
||
Deferred revenue, non-current
|
314
|
|
|
378
|
|
||
Deferred rent
|
20
|
|
|
25
|
|
||
Warrant liability
|
5,078
|
|
|
6,601
|
|
||
Loan payable, long term
|
14,352
|
|
|
14,252
|
|
||
Total liabilities
|
23,122
|
|
|
24,973
|
|
||
Commitments and contingencies
|
|
|
|
||||
Stockholders’ equity:
|
|
|
|
||||
Preferred stock, $0.001 par value, authorized 5,000,000 shares as of March 31, 2017, and December 31, 2016; 0 shares issued and outstanding as of March 31, 2017, and December 31, 2016
|
—
|
|
|
—
|
|
||
Common stock, $0.001 par value, 125,000,000 shares authorized as of March 31, 2017, and December 31, 2016; 25,536,533 and 24,609,411 shares issued and outstanding as of March 31, 2017, and December 31, 2016, respectively
|
25
|
|
|
24
|
|
||
Additional paid-in capital
|
218,567
|
|
|
214,918
|
|
||
Accumulated deficit
|
(185,059
|
)
|
|
(180,123
|
)
|
||
Total stockholders’ equity
|
33,533
|
|
|
34,819
|
|
||
Total liabilities and stockholders’ equity
|
$
|
56,655
|
|
|
$
|
59,792
|
|
|
Three Months Ended March 31,
|
||||||
|
2017
|
|
2016
|
||||
Revenue
|
$
|
64
|
|
|
$
|
64
|
|
Operating expenses:
|
|
|
|
||||
Research and development, net
|
4,020
|
|
|
4,743
|
|
||
Selling, general and administrative
|
2,060
|
|
|
2,533
|
|
||
Total operating expenses
|
6,080
|
|
|
7,276
|
|
||
Loss from operations
|
(6,016
|
)
|
|
(7,212
|
)
|
||
Other (income) expense:
|
|
|
|
||||
Amortization of debt discount
|
100
|
|
|
—
|
|
||
Interest income
|
(69
|
)
|
|
(28
|
)
|
||
Interest expense
|
345
|
|
|
—
|
|
||
Warrant liability fair value adjustment
|
(1,523
|
)
|
|
—
|
|
||
Total other income
|
(1,147
|
)
|
|
(28
|
)
|
||
Net loss
|
$
|
(4,869
|
)
|
|
$
|
(7,184
|
)
|
Warrant liability fair value adjustment
|
(1,523
|
)
|
|
—
|
|
||
Net loss attributable to common stockholders - diluted
|
$
|
(6,392
|
)
|
|
$
|
(7,184
|
)
|
Net loss per share attributable to common stockholders - basic
|
|
|
|
||||
Net loss per share - basic
|
$
|
(0.19
|
)
|
|
$
|
(0.52
|
)
|
Net loss per share attributable to common stockholders - diluted
|
|
|
|
||||
Net loss per share - diluted
|
$
|
(0.25
|
)
|
|
$
|
(0.52
|
)
|
Weighted average common shares outstanding:
|
|
|
|
||||
Basic
|
25,364,429
|
|
|
13,905,613
|
|
||
Diluted
|
25,562,027
|
|
|
13,905,613
|
|
|
Three Months Ended March 31,
|
||||||
|
2017
|
|
2016
|
||||
Cash flows from operating activities:
|
|
|
|
||||
Net loss
|
$
|
(4,869
|
)
|
|
$
|
(7,184
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
||||
Depreciation
|
1
|
|
|
3
|
|
||
Stock-based compensation expense
|
396
|
|
|
274
|
|
||
Write off of deferred offering costs
|
—
|
|
|
111
|
|
||
Amortization of investment premium
|
100
|
|
|
—
|
|
||
Amortization of debt discount
|
100
|
|
|
—
|
|
||
Change in fair value of Warrant Liability
|
(1,523
|
)
|
|
—
|
|
||
Changes in deferred rent
|
(5
|
)
|
|
—
|
|
||
Changes in operating assets and liabilities:
|
|
|
|
||||
Prepaid expenses, other assets, and deferred costs
|
(549
|
)
|
|
(477
|
)
|
||
Accounts payable and accrued expenses
|
(359
|
)
|
|
186
|
|
||
Accrued severance and retention cost obligations
|
—
|
|
|
(1,809
|
)
|
||
Deferred revenue
|
(64
|
)
|
|
(64
|
)
|
||
Net cash used in operating activities
|
(6,772
|
)
|
|
(8,960
|
)
|
||
Cash flows from investing activities:
|
|
|
|
||||
Maturities of investments
|
6,000
|
|
|
—
|
|
||
Purchases of property and equipment
|
(2
|
)
|
|
(14
|
)
|
||
Purchase of investments
|
(18,161
|
)
|
|
—
|
|
||
Net cash used in investing activities
|
(12,163
|
)
|
|
(14
|
)
|
||
Cash flows from financing activities:
|
|
|
|
||||
Proceeds from common stock issued
|
3,277
|
|
|
—
|
|
||
Payments of deferred costs and underwriting discounts and commissions
|
(108
|
)
|
|
—
|
|
||
Proceeds from employee stock purchase plan issuance
|
18
|
|
|
5
|
|
||
Net cash provided by financing activities
|
3,187
|
|
|
5
|
|
||
Net decrease in cash and cash equivalents
|
(15,748
|
)
|
|
(8,969
|
)
|
||
Cash and cash equivalents, beginning of period
|
35,656
|
|
|
46,985
|
|
||
Cash and cash equivalents, end of period
|
$
|
19,908
|
|
|
$
|
38,016
|
|
Supplemental cash flow information:
|
|
|
|
||||
Cash paid for interest
|
$
|
345
|
|
|
$
|
—
|
|
Cash received for interest
|
$
|
60
|
|
|
$
|
28
|
|
Noncash financing and investing activities:
|
|
|
|
||||
Deferred offering costs included in accounts payable and accrued expenses
|
$
|
—
|
|
|
$
|
25
|
|
Deferred offerings cost reclassed to additional paid in capital
|
$
|
10
|
|
|
$
|
—
|
|
1.
|
Description of Business and Basis of Preparation
|
•
|
a base prospectus which covers the offering, issuance and sale by the Company of up to a maximum aggregate offering price of
$150.0 million
of the Company's common stock, preferred stock, debt securities and warrants, including common stock or preferred stock issuable upon conversion of debt securities, common stock issuable upon conversion of preferred stock, or common stock, preferred stock or debt securities issuable upon the exercise of warrants (the "Shelf Registration"), and
|
•
|
a prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of
$40.0 million
of the Company's common stock that may be issued and sold under a sales agreement with Cowen and Company, LLC ("Cowen"). On April 10, 2016, the Company terminated the sales agreement with Cowen, and on April 11, 2016, entered
into a Controlled Equity Offering Sales Agreement
SM
(the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”). Pursuant to the Sales Agreement, the Company may sell from time to time, at its option, up to an aggregate of
$40.0 million
of the Company’s common stock, through Cantor, as sales agent (the “ATM Offering”). Pursuant to the Sales Agreement, sales of the common stock, if any, will be made under the Company’s previously filed and currently effective registration statement on Form S-3
(File No. 333-207705)
.
|
2.
|
Summary of Significant Accounting Policies
|
|
|
Three Months Ended March 31,
|
||||||
|
|
2017
|
|
2016
|
||||
Research and development expense, gross
|
|
$
|
4,039
|
|
|
$
|
4,962
|
|
Less: Reimbursement of research and development expense
|
|
19
|
|
|
219
|
|
||
Research and development expense, net of reimbursements
|
|
$
|
4,020
|
|
|
$
|
4,743
|
|
•
|
Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;
|
•
|
Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and
|
•
|
Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances.
|
|
March 31,
|
||||
|
2017
|
|
2016
|
||
Warrants to purchase Series C-1 Preferred
|
14,033
|
|
|
14,033
|
|
Warrants to purchase common stock associated with Loan Agreement
|
122,435
|
|
|
—
|
|
Stock options
|
2,770,029
|
|
|
1,450,453
|
|
3.
|
Short-term
Investments
|
|
|
|
|
|
||||||||||||
|
|
Amortized Cost
|
|
Unrealized Gains
|
|
Unrealized Losses
|
|
Fair Value
|
||||||||
U.S. government securities
|
|
$
|
34,991
|
|
|
$
|
35
|
|
|
$
|
70
|
|
|
$
|
34,956
|
|
Total short-term investments
|
|
$
|
34,991
|
|
|
$
|
35
|
|
|
$
|
70
|
|
|
$
|
34,956
|
|
4.
|
Prepaid Expenses and Other Current Assets
|
|
March 31, 2017
|
|
December 31, 2016
|
||||
Prepaid SCY-078 development services
|
$
|
121
|
|
|
$
|
153
|
|
Prepaid insurance
|
87
|
|
|
243
|
|
||
Other prepaid expenses
|
93
|
|
|
71
|
|
||
Other receivable due from R-Pharm
|
252
|
|
|
233
|
|
||
Other current assets
|
138
|
|
|
41
|
|
||
Total prepaid expenses and other current assets
|
$
|
691
|
|
|
$
|
741
|
|
5.
|
Accrued Expenses
|
|
March 31, 2017
|
|
December 31, 2016
|
||||
Accrued research and development expenses
|
$
|
596
|
|
|
$
|
318
|
|
Accrued employee bonus compensation
|
203
|
|
|
730
|
|
||
Employee withholdings
|
6
|
|
|
22
|
|
||
Other accrued expenses
|
252
|
|
|
198
|
|
||
Total accrued expenses
|
$
|
1,057
|
|
|
$
|
1,268
|
|
6.
|
Borrowings
|
2017
|
$
|
—
|
|
2018
|
4,500
|
|
|
2019
|
6,000
|
|
|
2020
|
4,500
|
|
|
Total principal payments
|
15,000
|
|
|
Final fee due at maturity
|
750
|
|
|
Total principal and final fee payment
|
15,750
|
|
|
Unamortized discount and debt issuance costs
|
(1,398
|
)
|
|
Less current portion
|
—
|
|
|
Loan payable, long term
|
$
|
14,352
|
|
7.
|
Commitments and Contingencies
|
March 31, 2017 to December 31, 2017
|
$
|
231
|
|
2018
|
182
|
|
|
Thereafter
|
—
|
|
|
Total
|
$
|
413
|
|
8.
|
Stockholders' Equity
|
|
Shares of
Common Stock |
|
Common Stock
|
|
Additional Paid-in Capital
|
|
Accumulated Deficit
|
|
Total Stockholders' Equity
|
|||||||||
Balance, December 31, 2016
|
24,609,411
|
|
|
$
|
24
|
|
|
$
|
214,918
|
|
|
$
|
(180,123
|
)
|
|
$
|
34,819
|
|
Cumulative stock-based compensation forfeiture adjustment
|
—
|
|
|
—
|
|
|
67
|
|
|
(67
|
)
|
|
—
|
|
||||
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
(4,869
|
)
|
|
(4,869
|
)
|
||||
Stock-based compensation expense
|
—
|
|
|
—
|
|
|
396
|
|
|
—
|
|
|
396
|
|
||||
Common stock issued through employee stock purchase plan
|
7,667
|
|
|
—
|
|
|
17
|
|
|
—
|
|
|
17
|
|
||||
Common stock issued under Shelf Registration, net of expenses
|
919,455
|
|
|
1
|
|
|
3,169
|
|
|
—
|
|
|
3,170
|
|
||||
Balance, March 31, 2017
|
25,536,533
|
|
|
$
|
25
|
|
|
$
|
218,567
|
|
|
$
|
(185,059
|
)
|
|
$
|
33,533
|
|
|
March 31, 2017
|
|
December 31, 2016
|
||
Outstanding stock options
|
2,770,029
|
|
|
1,819,444
|
|
Outstanding Series C-1 Preferred warrants
|
14,033
|
|
|
14,033
|
|
Warrants to purchase common stock associated with June 2016 Public Offering
|
4,218,750
|
|
|
4,218,750
|
|
Warrants to purchase common stock associated with Loan Agreement
|
122,435
|
|
|
122,435
|
|
For possible future issuance under 2014 Equity Incentive Plan (Note 9)
|
702,712
|
|
|
668,921
|
|
For possible future issuance under Employee Stock Purchase Plan (Note 9)
|
94,082
|
|
|
72,338
|
|
For possible future issuance under 2015 Inducement Plan (Note 9)
|
165,000
|
|
|
165,000
|
|
Total common shares reserved for future issuance
|
8,087,041
|
|
|
7,080,921
|
|
9.
|
Stock-based Compensation
|
|
Number
of
Shares
|
|
Weighted-
Average
Exercise
Price
|
|
Weighted-
Average
Remaining
Contractual
Life (in years)
|
|
Aggregate
Intrinsic
Value ($000)
|
|||||
Outstanding — December 31, 2016
|
1,819,444
|
|
|
$
|
7.52
|
|
|
6.98
|
|
$
|
32
|
|
Granted
|
950,658
|
|
|
$
|
3.10
|
|
|
|
|
|
||
Exercised
|
—
|
|
|
$
|
—
|
|
|
|
|
|
||
Canceled
|
(73
|
)
|
|
$
|
9.64
|
|
|
|
|
|
||
Outstanding — March 31, 2017
|
2,770,029
|
|
|
$
|
6.00
|
|
|
7.36
|
|
$
|
14
|
|
Exercisable — March 31, 2017
|
1,138,970
|
|
|
$
|
8.26
|
|
|
5.49
|
|
$
|
9
|
|
Vested or expected to vest — March 31, 2017
|
2,770,029
|
|
|
$
|
6.00
|
|
|
7.36
|
|
$
|
14
|
|
|
Number of Shares
|
|
Weighted Average Grant Date Fair Value Per Share
|
|||
Non-vested at December 31, 2016
|
—
|
|
|
—
|
|
|
Granted
|
44,032
|
|
|
$
|
3.10
|
|
Vested
|
—
|
|
|
—
|
|
|
Forfeited
|
—
|
|
|
—
|
|
|
Non-vested at March 31, 2017
|
44,032
|
|
|
—
|
|
|
Three Months Ended March 31,
|
||||||
|
2017
|
|
2016
|
||||
Research and development
|
$
|
94
|
|
|
$
|
70
|
|
Selling, general and administrative
|
302
|
|
|
204
|
|
||
Total stock-based compensation expense
|
$
|
396
|
|
|
$
|
274
|
|
10.
|
Fair Value Measurements
|
|
|
|
|
Fair Value Hierarchy Classification
|
|||||||||||
|
|
Balance
|
|
Quoted Prices in Active Markets for Identical Assets (Level 1)
|
|
Significant Other Observable Inputs (Level 2)
|
|
Significant Unobservable Inputs (Level 3)
|
|||||||
December 31, 2016
|
|
|
|
|
|
|
|
|
|||||||
Cash on deposit
|
|
$
|
9,767
|
|
|
$
|
9,767
|
|
|
—
|
|
|
—
|
|
|
Money market funds
|
|
25,889
|
|
|
25,889
|
|
|
—
|
|
|
—
|
|
|||
Total assets
|
|
$
|
35,656
|
|
|
$
|
35,656
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Warrant liability
|
|
$
|
6,601
|
|
|
—
|
|
|
—
|
|
|
$
|
6,601
|
|
|
Total liabilities
|
|
$
|
6,601
|
|
|
—
|
|
|
—
|
|
|
$
|
6,601
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
March 31, 2017
|
|
|
|
|
|
|
|
|
|||||||
Cash on deposit
|
|
$
|
631
|
|
|
$
|
631
|
|
|
—
|
|
|
—
|
|
|
Money market funds
|
|
19,277
|
|
|
19,277
|
|
|
—
|
|
|
—
|
|
|||
Total assets
|
|
$
|
19,908
|
|
|
$
|
19,908
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Warrant liability
|
|
$
|
5,078
|
|
|
—
|
|
|
—
|
|
|
$
|
5,078
|
|
|
Total liabilities
|
|
$
|
5,078
|
|
|
—
|
|
|
—
|
|
|
$
|
5,078
|
|
Balance - January 1, 2017
|
$
|
6,601
|
|
Gain adjustment to fair value
|
(1,523
|
)
|
|
Balance - March 31, 2017
|
$
|
5,078
|
|
•
|
in vitro
data showing the antifungal activity of SCY-078 against the emerging drug-resistant fungal infection
Candida auris
; and
|
•
|
in vitro
data showing synergies of SCY-078 in combination with other antifungals against
Aspergillus
.
|
•
|
costs related to executing preclinical and clinical trials, including related drug formulation, manufacturing and other development;
|
•
|
salaries and personnel-related costs, including benefits and any stock-based compensation for personnel in research and development functions;
|
•
|
fees paid to consultants and other third parties who support our product candidate development and intellectual property protection;
|
•
|
other costs in seeking regulatory approval of our products; and
|
•
|
allocated overhead.
|
|
Three Months Ended March 31,
|
||||||||||||
|
2017
|
|
2016
|
|
Period-to-Period Change
|
||||||||
Revenue
|
$
|
64
|
|
|
$
|
64
|
|
|
—
|
|
|
—
|
%
|
Operating expenses:
|
|
|
|
|
|
|
|
||||||
Research and development, net
|
4,020
|
|
|
4,743
|
|
|
(723
|
)
|
|
(15.2
|
)%
|
||
Selling, general and administrative
|
2,060
|
|
|
2,533
|
|
|
(473
|
)
|
|
(18.7
|
)%
|
||
Total operating expenses
|
6,080
|
|
|
7,276
|
|
|
(1,196
|
)
|
|
(16.4
|
)%
|
||
Loss from operations
|
(6,016
|
)
|
|
(7,212
|
)
|
|
1,196
|
|
|
(16.6
|
)%
|
||
Other (income) expense:
|
|
|
|
|
|
|
|
||||||
Amortization of debt discount
|
100
|
|
|
—
|
|
|
100
|
|
|
—
|
|
||
Interest income
|
(69
|
)
|
|
(28
|
)
|
|
(41
|
)
|
|
146.4
|
%
|
||
Interest expense
|
345
|
|
|
—
|
|
|
345
|
|
|
—
|
|
||
Warrant liability fair value adjustment
|
(1,523
|
)
|
|
—
|
|
|
(1,523
|
)
|
|
—
|
|
||
Total other income
|
(1,147
|
)
|
|
(28
|
)
|
|
(1,119
|
)
|
|
3,996.4
|
%
|
||
Net loss
|
$
|
(4,869
|
)
|
|
$
|
(7,184
|
)
|
|
2,315
|
|
|
(32.2
|
)%
|
|
Three months ended March 31,
|
||||||
|
2017
|
|
2016
|
||||
Cash and cash equivalents, January 1
|
$
|
35,656
|
|
|
$
|
46,985
|
|
Net cash used in operating activities
|
(6,772
|
)
|
|
(8,960
|
)
|
||
Net cash used in investing activities
|
(12,163
|
)
|
|
(14
|
)
|
||
Net cash provided by financing activities
|
3,187
|
|
|
5
|
|
||
Net decrease in cash and cash equivalents
|
(15,748
|
)
|
|
(8,969
|
)
|
||
Cash and cash equivalents, March 31
|
$
|
19,908
|
|
|
$
|
38,016
|
|
•
|
the progress, costs, and timing of the clinical development of SCY-078, including the timing of the lifting of the clinical hold on the IV formulation of SCY-078;
|
•
|
the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;
|
•
|
the ability of product candidates to progress through clinical development successfully;
|
•
|
our need to expand our research and development activities;
|
•
|
the costs associated with securing, establishing and maintaining commercialization and manufacturing capabilities;
|
•
|
our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;
|
•
|
our need and ability to hire additional management and scientific and medical personnel;
|
•
|
the costs associated with our securities litigation and the outcome of that litigation;
|
•
|
our need to implement additional, as well as to enhance existing, internal systems and infrastructure, including financial and reporting processes and systems; and
|
•
|
the economic and other terms, timing and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future.
|
Item 3.
|
Quantitative and Qualitative Disclosure about Market Risk
|
Item 4.
|
Controls and Procedures
|
Item 1.
|
Legal Proceedings
|
Item 1A.
|
Risk Factors
|
Item 6.
|
Exhibits
|
SCYNEXIS, INC.
|
||
|
|
|
By:
|
|
/s/ Marco Taglietti, M.D.
|
|
|
Marco Taglietti, M.D.
|
|
|
Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
Date:
|
|
May 8, 2017
|
|
|
|
By:
|
|
/s/ Eric Francois
|
|
|
Eric Francois
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
|
|
|
Date:
|
|
May 8, 2017
|
Exhibit
Number
|
|
Description of Document
|
|
|
|
2.1
|
|
Asset Purchase Agreement, dated July 17, 2015, between the Company and Accuratus Lab Services, Inc. (Filed with the SEC as Exhibit 10.1 to our current report on Form 8-K, filed with the SEC on July 23, 2015, SEC File No. 001-36365, and incorporated by reference here).
|
|
|
|
3.1
|
|
Amended and Restated Certificate of Incorporation (Filed with the SEC as Exhibit 3.1 to our current report on Form 8-K, filed with the SEC on May 12, 2014, SEC File No. 001-36365, and incorporated by reference here).
|
|
|
|
3.2
|
|
Amended and Restated By-Laws (Filed with the SEC as Exhibit 3.4 to our Registration Statement on Form S-1, filed with the SEC on February 27, 2014, SEC File No. 333-194192, and incorporated by reference here).
|
|
|
|
4.1
|
|
Reference is made to Exhibits 3.1 and 3.2.
|
|
|
|
4.2
|
|
Fifth Amended and Restated Investor Rights Agreement, dated December 11, 2013 (Filed with the SEC as Exhibit 10.21 to our Registration Statement on Form S-1, filed with the SEC on February 27, 2014, SEC File No. 333-194192).
|
|
|
|
10.1
|
|
Compensation arrangements with certain executive officers (Filed with the SEC as Exhibit 10.34 to our Annual Report on Form 10-K filed with the SEC on March 13, 2017, SEC File No. 001-36365, and incorporated by reference here).
|
|
|
|
10.2
|
|
Amendment to Commitment to Services Agreement, dated January 17, 2017, between SCYNEXIS, Inc. and Accuratus Lab Services, Inc. (Filed with the SEC as Exhibit 10.35 to our Annual Report on Form 10-K filed with the SEC on March 13, 2017, SEC File No. 001-36365, and incorporated by reference here).
|
|
|
|
12.1
|
|
Statement Re Computation of Ratio of Earnings to Fixed Charges.
|
|
|
|
31.1
|
|
Certification of Chief Executive Officer pursuant to Rule 13-a-14(a) or Rule 15(d)-14(a) of the Exchange Act
|
|
|
|
31.2
|
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act
|
|
|
|
32.1
|
|
Certification of Chief Executive Officer and Chief Financial Officer pursuant to 13a-14(b) or 15d-14(b) of the Exchange Act
|
|
|
|
101.INS
|
|
XBRL Instance Document
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Schema Linkbase Document
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Calculation Linkbase Document
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Definition Linkbase Document
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Labels Linkbase Document
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Presentation Linkbase Document
|
1 Year Scynexis Chart |
1 Month Scynexis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions